In small cell lung cancer (SCLC), long-term follow-up with immunotherapy and randomized studies of lurbinectedin (Zepzelca) will unveil the next chapter of treatment decision making, explained Benjamin Drapkin, MD, PhD, adding that nonresponders to checkpoint inhibitors remain a key challenge.
“We have a lot of challenges in the first-line [setting] yet to overcome, including the 80% to 90% of patients who don't derive benefit and identifying the patients who do,” said Drakin. “In the second-line setting, there are a lot of new agents that are being tested, such as lurbinectedin, that show promising activity. [Physicians should] stay tuned for the randomized controlled trials that will,hopefully, show some superiority.” ...
